Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Gastroenterology_Gastrointestinal (to include Liver, Pancreas & metabolic dysfunction-associated steatotic liver disease (MASLD), Gout, MASH (Metabolic dysfunction-associated steatohepatitis), formerly, NASH (Non-Alcoholic SteatoHepatitis)Non-Alcoholic SteatoHepatitis (NASH)
CinDome

Organization & Developments: CinDome

Parents

*Drugs for treating gastrointestinal diseases
*Gastroparesis is an area of high unmet medical need, impacting an estimated 12-16 million people in the U.S. alone, with an incidence rate growing on pace with diabetes and no U.S. Food and Drug Administration (FDA) approved long-term treatment option.
*Provides drugs for treating diseases and developing a novel chemical entity, CIN-102, through the process of deuteration for treatment for chronic gastroparesis.